Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

ACEP Board Approves tPA Clinical Policy

By ACEP Now | on August 13, 2015 | 1 Comment
Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
ACEP Board Approves tPA Clinical Policy
Image Credit: © SHUTTERSTOCK.COM

ACEP’s “Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department” was approved by the Board of Directors in its June 24, 2015, meeting in Dallas. The 2015 tissue plasminogen activator (tPA) policy revised one passed in 2012.

You Might Also Like
  • Comment Period for tPA Clinical Policy Closing Soon
  • Recommendation to Update tPA Policy Approved by ACEP Board
  • Clinical Policy on tPA for Ischemic Stroke Important for Emergency Medicine
Explore This Issue
ACEP Now: Vol 34 – No 08 – August 2015
Table 1: Recommendations for tPA Use for Managing Acute Ischemic Stroke

(click for larger image)
Table 1: Recommendations for tPA Use for Managing Acute Ischemic Stroke

A writing subcommittee of the ACEP Clinical Policies Committee, chaired by Michael D. Brown, MD, FACEP, conducted a systematic review of the literature to derive evidence-based recommendations to answer two clinical questions. The table (right) displays the 2015 draft recommendations on the left and the final published recommendations, which incorporate feedback from the ACEP member comment period, on the right.

Among the 50 comments received on the draft policy, some were more impactful than others. For example, some appropriately pointed out that the draft Level A harm statement was not action oriented, which is one of the primary aims in developing recommendations that are useful to clinicians.
—Michael D. Brown, MD, FACEP

As Dr. Brown explained, “Among the 50 comments received on the draft policy, some were more impactful than others. For example, some appropriately pointed out that the draft Level A harm statement was not action oriented, which is one of the primary aims in developing recommendations that are useful to clinicians. Therefore, the statement regarding considering the risk of sICH associated with tPA was moved to follow the action-oriented Level B recommendations. Other comments highlighted the fact that the risk of sICH is dependent upon the characteristics of the individual patient; thus, including average estimates of risks in the recommendation could be misleading. However, estimates for potential benefit and harm (ie, number needed to treat, number needed to harm) based on the clinical trial with the highest class of evidence for each critical question (Class I for Question 1 and Class II for Question 2) were retained in Appendix D as examples of how one might initiate the process of shared decision making.”

So what in the original 2012 policy was changed in the 2015 policy?

Here’s a summary of the updates:

  • This revised policy utilized an updated clinical policy development process that includes formally trained methodologists grading the research evidence.
  • There were no Level A recommendations since this level requires a high degree of clinical certainty.
  • Although Level B recommendations reflect a moderate degree of clinical certainty, the purposeful choice of wording in the recommendations differentiates the action-oriented statements for Question 1 and Question 2.
  • The Level C recommendations, based on consensus opinion, emphasize the importance of shared decision making when feasible.
  • The potential for benefit and harm associated with the use of intravenous tissue plasminogen activator in acute ischemic stroke is summarized in Appendix D of the policy.

This clinical policy is posted on the ACEP Web site at www.acep.org/clinicalpolicies. It will be published in Annals of Emergency Medicine in September 2015.

Pages: 1 2 | Single Page

Topics: ACEPACEP BoardAmerican College of Emergency PhysiciansClinical GuidelineCritical CareEmergency MedicineProcedures and SkillsStroke

Related

  • EM Runs in the Family

    February 26, 2025 - 0 Comment
  • Navigating Strict State Abortion Laws

    January 5, 2025 - 1 Comment
  • Post-Tonsillectomy Hemorrhage: A Three-Pronged Approach

    January 5, 2025 - 3 Comments

Current Issue

ACEP Now May 03

Read More

About the Author

ACEP Now

View this author's posts »

One Response to “ACEP Board Approves tPA Clinical Policy”

  1. April 10, 2018

    Podcast #90 - Indefinite Evidence and Biased Reporting « FOAM EMS Reply

    […] The American College of Emergency Physicians in 2015 did update their guidelines and did so where “There were no relevant industry relationships disclosed by the subcommittee members” which is very different than most other groups.  They were not able to make any Level A recommendations but did make Level B and C recommendations.  This matters for a number of reasons but ultimately they talked about how tPA “should be offered and may be given” to select patients within three (3) hours of symptom onset and that “tPA may be offered and may be given to carefully selected patients” within 3 to 4.5 hours after symptom onset in appropriate centers.  In both cases, shared decision making is encouraged when feasible.  The reason why this matters is that the liberal language allows for more careful consideration based on the complex nature of this disease process to help tailor care to individual patients. […]

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603